{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:08:07Z","timestamp":1769702887406,"version":"3.49.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>A 69-year-old female was admitted to the hospital with abdominal pain and distension. Gastroscopy revealed an irregular protruding lesion on the lesser curvature of the gastric fundus, and pathological examination indicated moderately to poorly differentiated adenocarcinoma. Enhanced abdominal computed tomography (CT) identified a space-occupying lesion at the gastric fundus with multiple enlarged lymph nodes. The initial diagnosis was moderately to poorly differentiated adenocarcinoma, cT3N3M0 (Stage IIIa). The patient subsequently underwent neoadjuvant therapy comprising albumin-bound paclitaxel, camrelizumab, oxaliplatin, and S-1.After four cycles, the tumor significantly reduced in size, with restaging at yT2N2M0 (Stage IIb). Following multidisciplinary team (MDT) consultation, the patient underwent radical total gastrectomy with esophagojejunostomy. Postoperative recovery was uneventful, and the patient was discharged in improved condition. Notably, postoperative pathological analysis revealed a neuroendocrine tumor, demonstrating an alteration in tumor histology after neoadjuvant therapy for gastric cancer (GC).<\/jats:p>","DOI":"10.3389\/fonc.2026.1692675","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:23:27Z","timestamp":1769664207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Alteration of tumor characteristics following neoadjuvant treatment in gastric adenocarcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Lingzhi","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Gansu Provincial Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanying","family":"Ma","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Gansu University of Traditional Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Gansu University of Traditional Chinese Medicine","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Gansu Provincial Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Longxi County First People\u2019s Hospital","place":["Longxi, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Gansu Provincial Hospital","place":["Lanzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.9.1318","article-title":"Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a","volume":"7","author":"Wilke","year":"1989","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1038\/s41467-022-35431-x","article-title":"Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates ofincidence and mortality","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i16.2452","article-title":"Updates on global epidemiology, risk andprognostic factors ofgastric cancer","volume":"29","author":"Yang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B5","article-title":"Gastric cancer: rapid evidence review","volume":"111","author":"Mott","year":"2025","journal-title":"Am Fam Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1528529","article-title":"Prospects for the application ofpathological response rate in neoadjuvant","volume":"15","author":"Bao","year":"2025","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00676-4","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S\u20131 versus adjuvant","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00297-7","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S\u20131 versus adjuvant","volume":"22","author":"Zhang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2020_87-306","article-title":"Adenocarcinoma and neuroendocrine collision tumor in a giant gastric hyperplastic","volume":"87","author":"Park","year":"2020","journal-title":"J Nippon Med Sch"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000534427","article-title":"Correlation of Neuroendocrine differentiation with a distinctively suppressive","volume":"114","author":"Zou","year":"2024","journal-title":"Neuroendocrinology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143712","article-title":"Grade progression and intrapatient tumor heterogeneity as potential contributors","volume":"15","author":"Varghese","year":"2023","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-019-00213-0","article-title":"Dilemmas in diagnosis and management of gastroenteropancreatic mixed","volume":"51","author":"Desai","year":"2020","journal-title":"J Gastrointest Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.02.003","article-title":"Expression of neuroendocrine markers in non\u2013neuroendocrine endometrial","volume":"51","author":"Moritz","year":"2019","journal-title":"Pathology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i19.2076","article-title":"Mixed neuroendocrine\u2013non\u2013neuroendocrine neoplasms ofthe digestive system: A","volume":"28","author":"Toor","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First\u2013line nivolumab plus chemotherapy versus chemotherapy alone for advanced","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30791-5","article-title":"Ramucirumab with cisplatin and fluoropyrimidine as first\u2013line therapy in patients","volume":"20","author":"Fuchs","year":"2019","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","article-title":"Japanese gastric cancer treatment guidelines 2018 (5th edition)","volume":"24","year":"2021","journal-title":"Gastric Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2022.06.002","article-title":"Gastroenteropancreatic neuroendocrine tumors","volume":"51","author":"Fernandes","year":"2022","journal-title":"Gastroenterol Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.1064145","article-title":"Diagnostic work\u2013up and advancement in the diagnosis of gastroenteropancreatic","volume":"10","author":"Koffas","year":"2023","journal-title":"Front Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S115054","article-title":"Prognostic value ofPD\u2013L1 and PD\u20131 expression in pulmonary neuroendocrine tumors","volume":"9","author":"Fan","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7150\/jca.13711","article-title":"The impact of PD\u2013L1 expression in patients with metastatic GEP\u2013NETs","volume":"7","author":"Kim","year":"2016","journal-title":"J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-55031-8_13","article-title":"Notch pathway: A journey from notching phenotypes to cancer immunotherapy","volume":"1287","author":"Monticone","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175217","article-title":"Notch signaling suppresses neuroendocrine differentiation and alters the immune","volume":"134","author":"Ku","year":"2024","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115600","article-title":"The placental gene PEG10 promotes progression ofNeuroendocrine prostate cancer","volume":"44","author":"Akamatsu","year":"2025","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1158\/1078-0432.CCR-21-3058","article-title":"Expanding therapeutic opportunities for extrapulmonary neuroendocrine carcinoma","volume":"28","author":"Frizziero","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","article-title":"Current knowledge of small cell lung cancer transformation from non\u2013small cell","volume":"94","author":"Giaccone","year":"2023","journal-title":"Semin Cancer Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1692675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:23:27Z","timestamp":1769664207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1692675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1692675"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1692675","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1692675"}}